Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder … – Markets Insider
|
Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder …
Markets Insider SAN DIEGO, Oct. 16, 2017 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced initiation of a clinical trial evaluating its investigational new drug PEGPH20 with atezolizumab (TECENTRIQ®), an anti-PDL1 cancer immunotherapy … Halozyme Therapeutics (HALO) Commences Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In … |
